Narcolepsy with cataplexy affects approximately one in 2,000-3,000 people in most societies, 1 but about 80% of individuals are thought to remain undiagnosed despite recent refinements to diagnostic criteria. 2 The negative social impact of narcolepsy with cataplexy has been extensively studied, and includes impairment in driving skill, high prevalence of car, machine or domestic accidents and altered professional performance leading to unemployment, frequent changes of job, working disability and early retirement. [3] [4] [5] In the past, standard treatment has consisted of amphetamines for excessive daytime sleepiness (EDS) and antidepressants for cataplexy.
Physicians provided the patients with the contact details of a countryspecific fieldwork agency and requested that the patients contact the agency to express their interest in participating in the study. Enrolment into the study took place after the completion of a structured telephone screening questionnaire, undertaken by the fieldwork agency. Entry criteria included a Ullanlinna Narcolepsy Scale (UNS) score of 10-44 and the identification of a partner or friend to participate in the research. The UNS is a simple 11-item questionnaire-based scale (range 0-44) addressing the two main features of narcolepsy: abnormal sleeping tendency and cataplexy. 10 Patients enrolled into the study along with their partner or friend underwent a face-to-face interview with trained fieldwork agents who individually and privately administered the Patient or Partner/Friend Questionnaires. The patient's questionnaire included the Short Form 36 (SF-36), and patients were also asked to complete a seven-day diary form assessing their naps, cataplexy, drug usage, sleep latency and maintenance and ability to perform tasks. Interviewers provided instructions on how to complete this diary form. The physicians, who were expert in the management of narcoplexy, completed the Physician Questionnaire after the patient had agreed to participate in the study. The Physician Questionnaire included questions on symptom ratings, symptoms that required further improvement, treatments prescribed and the physician's view of the patient's commitment to and satisfaction with treatment.
Statistical Analysis
The SPSS statistics package was used to analyse the data from the respondents. Where comparisons were made, statistical significance was tested using the chi-squared test for categorical data and student's t-test for two-group comparisons of means. Descriptive statistics such as frequency analysis were reported in the form of percentages.
Comparisons were also made between the views of patients and those of physicians and partners/friends on the impact of symptoms on quality of life. A difference of three on a 10-point weighting scale Narcolepsy symptoms) between the views of patients for each of the symptoms and those of physicians and/or partners/friends was deemed to be clinically relevant.
Results

Patient Characteristics
Of the 67 patients included in the study, 31 (46%) were men. Precise ages were not requested, but patients were categorised into seven age groups ranging from 19 to >71 years (44.8% were aged ≤40 years; 55.2% were aged >40 years). Their UNS score ranged from 10 Daytime medications taken during the study period were modafinil (62.7%), methylphenidate (19.4%) and antidepressants, including venlafaxine (11.9%), clomipramine (11.9%), fluoxetine (7.5%), paroxetine (4.5%) and dextroamphetamine (3.0%). Sodium oxybate was taken at night by 26.9% of the patients. Overall, 7.5% of the patients were extremely satisfied with their current treatment, 22.4% were very satisfied, 35.8% were satisfied, 26.9% were less than satisfied and 6%
were unsatisfied, and in 1.5% no view was stated.
Symptom Frequency
The frequency with which patients experienced the various symptoms of narcolepsy is shown in Figure 1 . Despite standard treatments, 70% of patients reported EDS every day and 31% had daily cataplexy. Of note, 63% reported nightly problems of staying asleep and 15% had trouble getting to sleep each night, highlighting the night-time sleep abnormalities.
Quality of Life
The impact of the patient's symptoms on his/her quality of life as estimated by the SF-36 is shown in Figure 2 . These values have been compared with norms for the general US population. 11 Patients had significantly lower scores than US norms in all domains (p<0.001; p<0.05 for role emotional) except bodily pain. The statistically significant differences were greater in patients with a UNS score >25 compared with those with a score ≤25.
The influence of individual symptoms on the patient's SF-36 domains was assessed. This analysis is not able to demonstrate the influence of EDS and cataplexy on the individual SF-36 domains because they occurred so frequently. Statistically significant influences were observed for the following symptoms across individual SF-36 domains: trouble getting to sleep influenced bodily pain (p<0.01) and physical functioning (p<0.05); mood disorders influenced mental health (p<0.01), vitality (p<0.01) and role emotional (p<0.05).
Day-to-day Activities and Accidents
A range of day-to-day activities were affected by the patient's narcolepsy: 56.7% of patients did not visit the cinema or theatre due to their narcolepsy, while relationships with others were affected in 28.4% of patients. Other activities affected included playing sports and general household chores, with only 16.4% of patients reporting that their narcolepsy had no effect on their day-to-day activities.
Narcolepsy had caused at least one accident at home or at work in 32.9% of patients during the previous year. Of those patients who held a driving licence, 24% had had a road traffic accident due to sleepiness in the previous year.
Response of Partner/Friend
Of the partners/friends who entered the study, 48% provided day-to-day care for the patient with narcolepsy and cataplexy, and 59.4% of these carers provided help for more than one hour per day. The impact of the patient's symptoms on the life of his or her partner/friend is shown in Figure 3 . For the partner/friend, there was a negative impact on social life 
8%).
The partners/friends recognised the problems of daytime sleepiness, concentration and mood/morale experienced by the patient (see Table 1 ). The partners/friends did not experience these symptoms themselves to the same degree, although 46.3% stated that they experienced negative mood/morale, 31.3% reported increased feelings of daytime sleepiness and 28.4% reported a loss of concentration (see Table 1 ).
Patient, Partner/Friend and Physician
Comparative Assessment
The frequency of the symptoms experienced by patients with narcolepsy was assessed independently by the patient, partner/friend and physician (see Figure 4 ). Significant differences in the frequency of symptoms observed were reported between: the patient and partner/friend for cataplexy (p<0.01); the patient and physician for cataplexy (p<0.05), mood disorders (p<0.01) and sleep paralysis (p<0.01); and the partner/friend and physician for mood disorder (p<0.05), microsleep (p<0.05) and trouble getting to sleep (p<0.05).
The impact of the symptoms on the patient's quality of life was also reported separately by the patient, partner/friend and physician. A three-point difference in the 10-point weighting scale used in this questionnaire was taken as clinically important, allowing for up to 1 SD.
The percentage of physicians and partners/friends who ranked the symptom impact on the patient's quality of life differently from the patient is shown in Table 2 .
For every symptom the physicians were more likely to underestimate than overestimate the impact on the patient's quality of life, particularly for trouble getting to sleep, trouble staying asleep and mood disorder.
The differences between the partner and the patient were statistically smaller than the differences between the physician and the patient, but for every symptom the partners also underestimated the impact relative to the patient.
Discussion
This study was designed to assess how effectively patients suffering from narcolepsy with cataplexy are managed with currently available treatments and to determine the continuing impact of the symptoms on the patients and those closest to them. The views of patients were also compared with those of their partner or close friend and their treating physician to understand ways in which care might be further improved.
The 18 participating European sleep centres identified 67 patients using agreed diagnostic criteria, all of whom were receiving standard treatment. No control group was included. Although 66% of patients were at least satisfied with their current medication, EDS continued to cause frequent symptoms, impaired quality of life with significant impact on day-to-day activities and frequent accidents, particularly road traffic accidents.
The least well-controlled symptoms were EDS and cataplexy, which are the main targets of current treatments, with other conventionally recognised symptoms occurring frequently, including difficulties with sleep and mood disorders. [12] [13] [14] These high frequencies of EDS and cataplexy contrast with the high level of satisfaction recorded by patients for their treatments. 13 These findings raise the possibility that the patient's satisfaction with his/her treatment may reflect his/her overall experience of the broad range of symptoms rather than a judgement relating to EDS and cataplexy. They also indicate that a substantial unmet need still exists in this patient population and that patients, and possibly their physicians, have a low expectation of success in symptom control.
The impact of symptoms on patient quality of life is demonstrated by the SF-36, where all domains were scored significantly lower than the US norms (p<0.001; p<0.05 for role emotional); this effect increased with the severity of the symptoms, as measured by the UNS. 10 Other more qualitative measures captured the negative day-to-day effects of the symptoms, with 84% of patients reporting a negative impact. The negative effects included the avoidance of social or sporting events and the strain that symptoms place on relationships and family/home life. These qualitative measures correlate with the 
